Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on uniQure. The associated price target remains the same with $70.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors including uniQure’s promising progress with AMT-130, a pioneering gene therapy for Huntington’s disease. The company has made significant strides in regulatory, manufacturing, and clinical areas, positioning AMT-130 for a Biologics License Application filing in the first quarter of 2026 and potential approval in the second half of 2026. Key milestones such as the submission of the final statistical analysis plan and the initiation of the process performance qualification campaign have been achieved, alongside FDA alignment on critical endpoints.
Additionally, uniQure’s pipeline is bolstered by other promising candidates like AMT-260, AMT-191, and AMT-162, which are advancing in Phase 1/2 trials. The company’s strong cash position of $377 million supports its operations into the second half of 2027, reinforcing its status as a top pick for 2025. The anticipated pivotal data readout in September and the potential for AMT-130 to be a first-in-class treatment for Huntington’s disease further underpin the Buy rating.
According to TipRanks, Trucchio is a 4-star analyst with an average return of 3.9% and a 39.38% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as uniQure, GH Research, and Sangamo Biosciences.
In another report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $47.00 price target.